Jul 07, 2026
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Jun 29, 2026
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Jun 18, 2026
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Jun 17, 2026
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Jun 08, 2026
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
Jun 04, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
Jun 03, 2026
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Jun 02, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
May 28, 2026
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
May 15, 2026
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
   1    2   3   4   5   6 
 <<   <   >   >> 
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.